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has also been proposed as an early noninvasive 
marker of pulmonary vascular disease and RV 
dysfunction in patients with HFpEF. In their 
analysis, Obokata et al4 found higher plasma lev‑
els of both C ‑terminal proET ‑1 and midregion‑
al proadrenomedullin in patients with HFpEF, 
both at baseline and on exertion. Apart from that, 
they reported a significant direct correlation with 
mean pulmonary arterial pressure and pulmonary 
artery wedge pressure, as well as an inverse re‑
lationship with pulmonary arterial compliance.
Another aspect suggesting a potential disease 
continuum between PAH and PH in HFpEF is 
a weaker response to targeted PAH ‑therapy in 
patients with PAH and concomitant risk factors 
for left heart disease, which raises suspicion that 
these factors may potentially contribute to such 
low therapeutic efficacy. A plausible explanation 
of the weaker response to treatment takes into 
account the potential impact of cardiovascular 
risk factors and comorbidities on developing sys‑
temic inflammation and coronary microvascular 
disease, with subsequent RV impairment, low‑
er exercise tolerance, and nonresponsiveness to 
PAH‑specific drugs, which act mainly on pulmo‑
nary circulation. Finally, in patients with atypi‑
cal PAH, a trend toward higher pulmonary artery 
wedge pressure and left ventricular end ‑diastolic 
pressure was observed, which raise RV afterload 
and impair RV function.2,5
In conclusion, research on atypical PAH pro‑
vides new insights suggesting a closer inter‑
play between PAH and PH in HFpEF and offers 
a hypothesis on a potential disease continuum 
between these 2 PH phenotypes. Further stud‑
ies are needed to elucidate a plausible etiologi‑
cal link between PAH and coexisting cardiovas‑
cular risk factors in order to stratify the thera‑
peutic response to targeted PAH ‑treatment in 
this population.
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To the editor Pulmonary arterial hypertension 
(PAH) is a heterogeneous clinical condition. Due 
to its hemodynamic features and pathophysio‑
logical mechanisms, it is categorized as a form 
of precapillary pulmonary hypertension (PH). 
However, progressive epidemiological changes 
in the demographic characteristics of individu‑
als with PAH are still providing new nosologi‑
cal insights in clinical practice. The article by Jo‑
nas and Kopeć1 referred to a challenging phe‑
notype of PAH, which still presents a hemody‑
namic profile compatible with precapillary PH, 
together with an increased prevalence of risk 
factors predisposing to left heart disease, par‑
ticularly to left ventricular diastolic dysfunc‑
tion. In the analysis involving patients enrolled 
in the COMPERA (Comparative, Prospective 
Registry of Newly Initiated Therapies for Pul‑
monary Hypertension) registry between May 
2007 and April 2015, Optiz et al2 first coined 
the term “atypical PAH,” while “PAH with comor‑
bidities” was subsequently provided in the rec‑
ommendations from the 2nd Cologne Consen‑
sus Conference 2018 to alternatively identify 
this hybrid PH phenotype.3 Although efforts 
were made to indicate peculiar features defining 
such a new PH entity, data from the literature 
suggested possible overlaps between the patho‑
biological mechanisms of PAH and PH regard‑
ing heart failure with preserved ejection frac‑
tion (HFpEF). These 2 PH phenotypes have been 
shown to share a neurohormonal basis predis‑
posing to right ventricular (RV) failure and pul‑
monary vascular disease. Endothelin ‑1 (ET ‑1) has 
been reported to play a pivotal role in the devel‑
opment of vascular abnormalities in PAH, in‑
cluding pulmonary vasoconstriction, smooth 
cell proliferation, and vascular remodeling. In 
contrast, the counterregulatory peptide adre‑
nomedullin is known for its cardioprotective 
effect on pulmonary circulation, including va‑
sodilatation and inhibition of vascular disrup‑
tion. The co ‑upregulation of both these pathobi‑
ological pathways has been described in animal 
models of PAH. Furthermore, their activation 
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still fulfilling the hemodynamic criteria of a pre‑
capillary disease. Furthermore, the authors found 
that older individuals with PAH compared with 
younger patients were less often diagnosed with 
idiopathic PAH and more often with PAH associ‑
ated with connective tissue disease. This account‑
ed for nearly 50% of cases diagnosed in the old‑
est age group, which may suggest an important 
role of altered immunity in the ethiology of PAH 
in the elderly.
The definitive distinction between PAH and 
a postcapillary disease may be challenging, es‑
pecially considering numerous technical require‑
ments and expertise needed to obtain reliable he‑
modynamic parameters. In  the case of multifac‑
torial diseases, single cut off values may be insuf‑
ficient to unequivocally separate disease entities. 
Additional provocative procedures, including vol‑
ume loading or exercise challenge, have not been 
sufficiently validated and thus are not endorsed 
by the current guidelines. Of note, HFpEF may 
also affect pulmonary circulation, leading to sec‑
ondary vascular remodeling, which further rein‑
forces the hypothesis on a spectrum of diseases 
between HFpEF with PH and PAH.
A growing number of patients with a new phe‑
notype of PH requires comprehensive diagnostic 
evaluation and close follow ‑up after initiation 
of treatment in the expert centers. As recently 
shown by McLaughlin et al,1 patients with PAH 
and a high number of risk factors for HFpEF are 
characterized by less favorable responsiveness 
to treatment. This involves drug ‑associated ad‑
verse events and clinical failure occurring in this 
patient group more frequently than in subjects 
without comorbidities. Future studies are there‑
fore needed to establish the most appropriate 
treatment strategies, since this challenging pop‑
ulation was often underrepresented or exclud‑
ed in recent large clinical trial protocols. Analyz‑
ing the relationship between age and right heart 
function during diagnosis and after initiation of 
treatment may help to further optimize treat‑
ment methods in this novel population.
In conclusion, the disparity between an increas‑
ing number of patients with a new, challenging 
PAH phenotype and lack of comprehensive clin‑
ical data need to be addressed in future research 
to establish safe and effective diagnostic work‑
up and therapeutic strategy for this population.
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Authors’ reply We would like to thank Riccardo 
Scagliola for his interesting comment to our ar‑
ticle on a new, challenging phenotype of pulmo‑
nary arterial hypertension (PAH), published in 
the December issue of Polish Archives of Internal 
Medicine (Pol Arch Intern Med).1 Although recent 
advances in treatment contributed to improving 
prognosis of patients with PAH, this population 
has in fact changed substantially during the last 
decades, which has been recently described as 
a novel phenotype of PAH, atypical PAH, or PAH 
with comorbidities. More prevalent features of 
heart failure with preserved ejection fraction (HF‑
pEF) in newly diagnosed patients with pulmo‑
nary hypertension (PH) made differential diag‑
nosis more challenging and raised questions re‑
garding a possible overlap between these 2 dis‑
ease entities (PAH and HFpEF with PH).
As recently shown, the observed shift in the ep‑
idemiology of PAH and the higher number of car‑
diovascular comorbidities in patients with PAH 
can be associated with an increasing age of diag‑
nosed patients. What is more, some of the main 
cardiovascular risk factors, including alterations 
in glucose and lipoprotein metabolism, can serve 
as prognostic factors and affect patients’ surviv‑
al.2-4 As reported in the analysis of recent ran‑
domized, placebo ‑controlled trials by Rose et al,5 
elderly patients were characterized by less se‑
vere hemodynamic impairment including lower 
baseline mean pulmonary arterial pressure and 
pulmonary vascular disease, despite worse func‑
tional impairment and a less favorable response 
to PAH ‑specific treatment, than their younger 
counterparts. This may be partially attributed to 
the presence of PH with more abundant risk fac‑
tors for left ventricular diastolic dysfunction, yet 
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